These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma. Wang Z Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001 [No Abstract] [Full Text] [Related]
4. Federal Trade Commission v. Actavis, Inc. and reverse-payment or pay-for-delay settlements. Sherkow JS Nat Biotechnol; 2013 Apr; 31(4):316-7. PubMed ID: 23563426 [No Abstract] [Full Text] [Related]
5. Pharmaceuticals and medical devices: cost savings. ; Steiner DJ Issue Brief Health Policy Track Serv; 2012 Jan; ():1-37. PubMed ID: 22403843 [No Abstract] [Full Text] [Related]
6. Pharmaceuticals and medical devices: FDA oversight. Issue brief. Berry MD Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449 [No Abstract] [Full Text] [Related]
7. The FTC v. Actavis roadmap: a guide to properly applying the rule of reason standard in reverse payment cases. Sharkey N J Leg Med; 2014; 35(3):445-66. PubMed ID: 25207633 [No Abstract] [Full Text] [Related]
8. Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door. Yang YT; Chen B; Bennett CL J Clin Oncol; 2016 Dec; 34(36):4320-4322. PubMed ID: 27998222 [No Abstract] [Full Text] [Related]
9. The "reverse payment paradox": an overview of the legality of reverse exclusionary payments in the pharmaceutical industry. Brockmeier MS Health Care Law Mon; 2010 Mar; 2010(3):2-10. PubMed ID: 20329564 [No Abstract] [Full Text] [Related]
11. The Myth of the Free Market for Pharmaceuticals. Conti RM; Frank RG; Cutler DM N Engl J Med; 2024 Apr; 390(16):1448-1450. PubMed ID: 38647106 [No Abstract] [Full Text] [Related]
12. Competition and antitrust enforcement in the changing pharmaceutical marketplace. Whitener MD Food Drug Law J; 1995; 50(2):301-7. PubMed ID: 10342998 [No Abstract] [Full Text] [Related]
14. The wake of FTC v. Actavis: practical implications on the pharmaceutical industry. Ritter M; Tempesta J; Ragusa P Pharm Pat Anal; 2014 Jul; 3(4):345-7. PubMed ID: 25291307 [No Abstract] [Full Text] [Related]
15. Pharmaceuticals and medical devices: FDA oversight. ; Berry MD Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845 [No Abstract] [Full Text] [Related]
16. Pharmaceuticals and medical devices: business practices. Steiner DJ Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889 [No Abstract] [Full Text] [Related]